ImmunityBio

ImmunityBio IBRX Stock

$6.02   -0.823726%
Add to favorites
Market Cap
$6.40B
LOW - HIGH [24H]
$5.83 - $6.17
VOLUME [24H]
$13.33M
P/E Ratio
0
Earnings per share
-$1.06
ISIN
US45256X1037
Price   Prediction

ImmunityBio Price Chart

Sorry, that's all we've gotfor now...

ImmunityBio (IBRX) stock price today is 6.02 USD on Tech Market Large (-0.82% on the day). Updated .

ImmunityBio IBRX Financial and Trading Overview

ImmunityBio stock price 6.02 USD
Previous Close 6.07 USD
Open 6.09 USD
Bid 4.38 USD x 200
Ask 39.9 USD x 4900
Day's Range 5.83 - 6.17 USD
52 Week Range 1.95 - 12.43 USD
Volume 13.3M USD
Avg. Volume 12.64M USD
Market Cap 6.4B USD
Beta (5Y Monthly) 0.174
PE Ratio (TTM) N/A
EPS (TTM) -1.06 USD
Forward Dividend & Yield N/A (0%)
Ex-Dividend Date N/A
1y Target Est 14.25 USD

IBRX Valuation Measures

Enterprise Value 7.37B USD
Trailing P/E N/A
Forward P/E -54.727272
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) 35.077847
Price/Book (mrq) N/A
Enterprise Value/Revenue 40.35
Enterprise Value/EBITDA -28.585

Trading Information

ImmunityBio Stock Price History

Beta (5Y Monthly) 0.174
52-Week Change 196.55%
S&P500 52-Week Change 13.32%
52 Week High 12.43 USD
52 Week Low 1.95 USD
50-Day Moving Average 8.59 USD
200-Day Moving Average 7.97 USD

IBRX Share Statistics

Avg. Volume (3 month) 12.64M USD
Avg. Daily Volume (10-Days) 15.81M USD
Shares Outstanding 1.06B
Float 410.68M
Short Ratio 8.32
% Held by Insiders 62.12%
% Held by Institutions 20.47%
Shares Short 126.08M
Short % of Float 31.14%
Short % of Shares Outstanding 11.84%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio N/A
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2025
Most Recent Quarter (mrq) September 30, 2026
Next Fiscal Year End December 31, 2026

Profitability

Profit Margin 0%
Operating Margin (ttm) -150.16%
Gross Margin 98.79%
EBITDA Margin -141.15%

Management Effectiveness

Return on Assets (ttm) -30.37%
Return on Equity (ttm) N/A

Income Statement

Revenue (ttm) 182.57M USD
Revenue Per Share (ttm) 0.18 USD
Quarterly Revenue Growth (yoy) 52.30%
Gross Profit (ttm) 180.36M USD
EBITDA -257716992 USD
Net Income Avi to Common (ttm) -1109654016 USD
Diluted EPS (ttm) -1.06
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 334.33M USD
Total Cash Per Share (mrq) 0.31 USD
Total Debt (mrq) 1.3B USD
Total Debt/Equity (mrq) N/A
Current Ratio (mrq) 4.27
Book Value Per Share (mrq) -1.078

Cash Flow Statement

Operating Cash Flow (ttm) -287564000 USD
Levered Free Cash Flow (ttm) -176333872 USD

Profile of ImmunityBio

Country United States
State CA
City San Diego
Address 3530 John Hopkins Court
ZIP 92121
Phone 844 696 5235
Website https://immunitybio.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 684

ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors; and 3M-052, a synthetic TLR7/8 agonist and 3M-052 formulations and related technology. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeOne Medicines Ltd. It has license agreement with 3M Innovative Properties Company and Access to Advanced Health Institute. ImmunityBio, Inc. is based in San Diego, California.

Q&A For ImmunityBio Stock

What is a current IBRX stock price?

ImmunityBio IBRX stock price today per share is 6.02 USD.

How to purchase ImmunityBio stock?

You can buy IBRX shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for ImmunityBio?

The stock symbol or ticker of ImmunityBio is IBRX.

Which industry does the ImmunityBio company belong to?

The ImmunityBio industry is Biotechnology.

How many shares does ImmunityBio have in circulation?

The max supply of ImmunityBio shares is 1.06B.

What is ImmunityBio Price to Earnings Ratio (PE Ratio)?

ImmunityBio PE Ratio is now.

What was ImmunityBio earnings per share over the trailing 12 months (TTM)?

ImmunityBio EPS is -1.06 USD over the trailing 12 months.

Which sector does the ImmunityBio company belong to?

The ImmunityBio sector is Healthcare.

ImmunityBio IBRX included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
us US Tech Composite IXIC US 25136.27 USD —
-0.91
7.74B USD — 24872.41 USD — 25423.09 USD — — 7.74B USD —
us Horizon Kinetics ISE Wealth Ind RCH US 4189.11 USD —
-0.06
— — 4162.92 USD — 4194.53 USD — — — —
us US Tech Global Select Market Com NQGS US 12378.66 USD —
-0.9
— — 12248.6 USD — 12520.36 USD — — — —
us Stlmt ID US Tech Biotechnology NBX US 4000.62 USD —
-1.26
— — 3927.42 USD — 4148.65 USD — — — —
us US Tech US 700 Small Cap Index NQUS700SC US 3020.37 USD —
-0.22
— — 2991.33 USD — 3035.56 USD — — — —
us US Tech AlphaDEX Multi Cap Growt NQDXUSMLTCG US 3748.08 USD —
-0.7
— — 3701.51 USD — 3782.39 USD — — — —
us US Tech Biotechnology NBI US 7211.27 USD —
-0.5
— — 7149.19 USD — 7238.9 USD — — — —
us US Tech Health Care IXHC US 1368.29 USD —
-0.34
— — 1358.68 USD — 1373.65 USD — — — —
$2.2T
Total marketcap
$76.28B
Total volume
BTC 59.40%   •   ETH 10.12%
Dominance
Select currency